The value of the monoclonal antibody (cancer antigen 125) in serial monitoring of ovarian cancer: a comparison with circulating immune complexes
- 1 October 1985
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 92 (10), 1054-1060
- https://doi.org/10.1111/j.1471-0528.1985.tb03003.x
Abstract
Summary. The use of circulating immune complexes and a commercial monocolonal antibody to ovarian cancer (CA125 kit) in monitoring progress in patients with ovarian cancer has been assessed. While changes in immune complexes were apparent in some patients with active progression of disease, the marked change in values and linear trend make the use of CA125 a useful clinical marker.This publication has 18 references indexed in Scilit:
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Circulating IgG-specific immune complexes as a potential tumor marker in gynecological malignanciesGynecologic Oncology, 1983
- An assessment of sequential measurements of immune complex levels in ovarian cancer patients with respect to clinical progressGynecologic Oncology, 1983
- Sequential Studies of Circulating Immune Complexes in Gynecological Malignancies*American Journal of Reproductive Immunology, 1982
- Reactivity of a monoclonal antibody with human ovarian carcinoma.JCI Insight, 1981
- Tumour markers with unknown functions in gynaecological neoplasiaArchiv für Gynäkologie, 1980
- Carcinoembryonic antigen in patients with residual ovarian cancerGynecologic Oncology, 1979
- A REVIEW OF IMMUNOLOGICAL ASPECTS OF GYNAECOLOGICAL MALIGNANCYBJOG: An International Journal of Obstetrics and Gynaecology, 1979
- Detection of Carcinoembryonie Antigen and Alphafetoprotein in Serum and Ascitic Fluid from Patients with Ovarian CancerAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1977